Improving Medication Adherence in Older African Americans With Diabetes
Primary Purpose
Type 2 Diabetes, Mild Cognitive Impairment
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Primary Care-Occupational Therapy
Enhanced Usual Care
Sponsored by

About this trial
This is an interventional prevention trial for Type 2 Diabetes focused on measuring Type 2 diabetes, Mild Cognitive Impairment
Eligibility Criteria
Inclusion Criteria:
- Age 60 years and older.
- Self-identified as African American, black, black American, or black/Caribbean.
- Type II DM (i.e., physician diagnosis and medication treatment).
- HbA1c level ≥ 7.5%.
- MCI, based on National Institute on Aging/Alzheimer's Association (NIA/AA) criteria.
- ≤ 80% adherence to an oral hypoglycemic medication or insuling, as documented during a run-in phase using a Medication Event Monitoring System (MEMS).
Exclusion Criteria:
- Dementia, based on National Institute on Aging/Alzheimer's Association criteria.
- DSM-V psychiatric disorder other than depressive disorders.
- End-stage renal disease requiring dialysis.
- Hearing/Vision (i.e., severe diabetic retinopathy) or motor (e.g., peripheral neuropathy) impairment that precludes research participation.
Sites / Locations
- Thomas Jefferson University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Primary Care-Occupational Therapy
Enhanced Usual Care
Arm Description
PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
Usual care enhanced with education and controls for attention
Outcomes
Primary Outcome Measures
Percent of Participants With Improvement in Hemoglobin A1c by 0.5%"
Percent of participants who had a reduction (improvement) of at least .5% in hemoglobin A1c from baseline to 6 months
Secondary Outcome Measures
Adherence as Measured By Percentage of Doses Taken as Prescribed
This was assessed objectively using a Medication Event Monitoring System (MEMS) bottle. The MEMS measured daily bottle openings continuously to assess adherence to insulin or an oral hypoglycemic agent. The adherence rate is the percent of doses that were taken as prescribed.
Full Information
NCT ID
NCT02174562
First Posted
June 20, 2014
Last Updated
August 6, 2020
Sponsor
Thomas Jefferson University
Collaborators
Johns Hopkins University
1. Study Identification
Unique Protocol Identification Number
NCT02174562
Brief Title
Improving Medication Adherence in Older African Americans With Diabetes
Official Title
Improving Medication Adherence in Older African Americans With Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
July 2014 (Actual)
Primary Completion Date
December 2019 (Actual)
Study Completion Date
December 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Thomas Jefferson University
Collaborators
Johns Hopkins University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This research aims to help older African Americans with diabetes and mild memory problems improve how they take their medications and control their diabetes. This may preserve their independence and health, prevent cognitive and functional decline, and reduce health care costs. As the population ages and becomes more racially diverse, finding ways to achieve these outcomes has great public health importance.
Detailed Description
The prevalence of type 2 diabetes (DM) in older persons is increasing rapidly. DM increases the risk for Mild Cognitive Impairment (MCI), which is a transition state between normal cognition and dementia that is often characterized by memory and executive function deficits. These deficits reduce adherence to DM medications, which worsens glycemic control and increases the risk for adverse DM-related health outcomes. Improving medication adherence may prevent these outcomes and reduce health care costs. This is important to all older persons with DM but particularly to older African Americans (AAs). They have twice the rate of DM, worse cognitive function, lower medication adherence, and worse glycemic control than whites. One million older AAs now have DM and their number will double by 2030. Because 30% also have MCI, low medication adherence is an important problem for them. This necessitates culturally relevant interventions that compensate for their cognitive deficits and improves their medication adherence and glycemic control. We propose a randomized controlled clinical trial to test the efficacy of a collaborative Primary Care-Occupational Therapy (PC-OT) intervention to lower hemoglobin A1c (HbA1c) levels in older AAs with DM, MCI, HbA1c ≥ 7.5%, and ≤ 80% adherence to an oral hypoglycemic medication. PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet). We will recruit 100 participants from primary care clinics and randomize them to PC-OT or Enhanced Usual Care (EUC). EUC is usual medical care plus low intensity DM education delivered by community health workers. Participants in both PC-OT and EUC will have 6 initial in-home treatment sessions over 3 months, and then 3 booster sessions during this 12 month study. The primary outcome is a reduction in HbA1c of 0.5%, which reduces the risk of adverse medical events. The primary efficacy analysis compares the proportion of participants in PC-OT and EUC who achieve this outcome at month 6 (short term effect) and at month 12 (maintenance effect). We will measure medication adherence using an electronic Medication Event Monitoring System, prescription refills, and self-reports. A secondary aim determines if improving medication adherence mediates PC-OT's impact on HbA1c levels. We will also evaluate PC-OT's effect on other DSM practices; ER visits and hospitalizations; cognition; function; mood; and quality of life; and PC-OT's costs and net financial benefits. This is the first study to determine if PCPs, collaborating with OTs (who are experts in developing strategies to compensate for cognitive/physical deficits), can improve medication adherence and glycemic control, and prevent cognitive and functional decline in older persons with DM and MCI. If PC-OT is effective in a high risk population of older AAs, its benefits may extend to all older persons with DM and have enormous public health significance.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Mild Cognitive Impairment
Keywords
Type 2 diabetes, Mild Cognitive Impairment
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
101 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Primary Care-Occupational Therapy
Arm Type
Experimental
Arm Description
PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
Arm Title
Enhanced Usual Care
Arm Type
Placebo Comparator
Arm Description
Usual care enhanced with education and controls for attention
Intervention Type
Behavioral
Intervention Name(s)
Primary Care-Occupational Therapy
Intervention Description
PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
Intervention Type
Behavioral
Intervention Name(s)
Enhanced Usual Care
Intervention Description
Usual care enhanced with education and attention
Primary Outcome Measure Information:
Title
Percent of Participants With Improvement in Hemoglobin A1c by 0.5%"
Description
Percent of participants who had a reduction (improvement) of at least .5% in hemoglobin A1c from baseline to 6 months
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Adherence as Measured By Percentage of Doses Taken as Prescribed
Description
This was assessed objectively using a Medication Event Monitoring System (MEMS) bottle. The MEMS measured daily bottle openings continuously to assess adherence to insulin or an oral hypoglycemic agent. The adherence rate is the percent of doses that were taken as prescribed.
Time Frame
4-6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 60 years and older.
Self-identified as African American, black, black American, or black/Caribbean.
Type II DM (i.e., physician diagnosis and medication treatment).
HbA1c level ≥ 7.5%.
MCI, based on National Institute on Aging/Alzheimer's Association (NIA/AA) criteria.
≤ 80% adherence to an oral hypoglycemic medication or insuling, as documented during a run-in phase using a Medication Event Monitoring System (MEMS).
Exclusion Criteria:
Dementia, based on National Institute on Aging/Alzheimer's Association criteria.
DSM-V psychiatric disorder other than depressive disorders.
End-stage renal disease requiring dialysis.
Hearing/Vision (i.e., severe diabetic retinopathy) or motor (e.g., peripheral neuropathy) impairment that precludes research participation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barry W Rovner, MD
Organizational Affiliation
Thomas Jefferson University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
33752964
Citation
Rovner BW, Casten RJ. Emergency department visits in African Americans with mild cognitive impairment and diabetes. J Diabetes Complications. 2021 May;35(5):107905. doi: 10.1016/j.jdiacomp.2021.107905. Epub 2021 Mar 16.
Results Reference
derived
PubMed Identifier
32043561
Citation
Rovner BW, Casten RJ, Piersol CV, White N, Kelley M, Leiby BE. Improving Glycemic Control in African Americans With Diabetes and Mild Cognitive Impairment. J Am Geriatr Soc. 2020 May;68(5):1015-1022. doi: 10.1111/jgs.16339. Epub 2020 Feb 11.
Results Reference
derived
Learn more about this trial
Improving Medication Adherence in Older African Americans With Diabetes
We'll reach out to this number within 24 hrs